Bicycle Therapeutics reports BT5528 Phase I dose escalation results: ORR 22% in ovarian, 67% in urothelial cancers

BICYCLE THERAPEUTICS PLC

Among 9 EphA2-positive ovarian patients, ORR 22% (1 CR, 1 PR), DCR 67%; median 4 prior therapies.
In 3 EphA2-positive urothelial patients, ORR and DCR 67% (2 PRs).
Safety differentiated from EphA2 ADCs: no treatment-related hemorrhage, low-grade neuropathy, rash, eye disorders.
RP2D established at 6.5 mg/m2 every other week; expansion cohorts for ovarian, urothelial, and basket cancers ongoing.
Enrollment ongoing in expansion cohorts of up to 56 patients; updates expected next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.